```
1
       10A NCAC 41A .0101 is proposed for amendment as follows:
 2
 3
                                REPORTABLE DISEASES AND CONDITIONS
       10A NCAC 41A .0101
 4
       (a)
               The following named diseases and conditions are declared to be dangerous to the public health and are
 5
       hereby made reportable within the time period specified after the disease or condition is reasonably suspected to
 6
       exist:
 7
                        acquired immune deficiency syndrome (AIDS) - 24 hours;
               (1)
 8
               (2)
                        anthrax - immediately;
 9
               (3)
                        botulism - immediately;
10
               (4)
                        brucellosis - 7 days;
11
               (5)
                        campylobacter infection - 24 hours;
12
               (6)
                        chancroid - 24 hours;
13
                        chikungunya virus infection - 24 hours;
               (7)
14
               (8)
                        chlamydial infection (laboratory confirmed) - 7 days;
15
               (9)
                        cholera - 24 hours:
16
               (10)
                        Creutzfeldt-Jakob disease – 7 days;
17
                        cryptosporidiosis – 24 hours;
               (11)
18
               (12)
                        cyclosporiasis – 24 hours;
19
                        dengue - 7 days;
               (13)
20
               (14)
                        diphtheria - 24 hours;
21
                        Escherichia coli, shiga toxin-producing - 24 hours;
               (15)
22
               (16)
                        ehrlichiosis – 7 days;
23
                        encephalitis, arboviral - 7 days;
               (17)
24
               (18)
                        foodborne disease, including Clostridium perfringens, staphylococcal, Bacillus cereus, and other
25
               and unknown causes - 24 hours;
26
               (19)
                        gonorrhea - 24 hours;
27
               (20)
                        granuloma inguinale - 24 hours;
28
                        Haemophilus influenzae, invasive disease - 24 hours;
               (21)
29
               (22)
                        Hantavirus infection – 7 days;
30
               (23)
                        Hemolytic-uremic syndrome – 24 hours;
31
               (24)
                        Hemorrhagic fever virus infection – immediately;
32
               (25)
                        hepatitis A - 24 hours;
33
                (26)
                        hepatitis B - 24 hours;
34
               (27)
                        hepatitis B carriage - 7 days;
35
               (28)
                        hepatitis C, acute – 7 days;
```

```
1
               (29)
                        human immunodeficiency virus (HIV) infection confirmed - 24 hours;
 2
               (30)
                        influenza virus infection causing death – 24 hours;
 3
                        legionellosis - 7 days;
               (31)
 4
               (32)
                        leprosy – 7 days;
 5
               (33)
                        leptospirosis - 7 days;
 6
               (34)
                        listeriosis – 24 hours;
 7
               (35)
                        Lyme disease - 7 days;
 8
               (36)
                        Lymphogranuloma venereum - 7 days;
 9
               (37)
                        malaria - 7 days;
10
               (38)
                        measles (rubeola) - 24 hours;
11
               (39)
                        meningitis, pneumococcal - 7 days;
12
               (40)
                        meningococcal disease - 24 hours;
13
                        Middle East respiratory syndrome (MERS) - 24 hours;
               (41)
14
               (42)
                        monkeypox - 24 hours;
15
               (43)
                        mumps - 7 days;
16
               (44)
                        nongonococcal urethritis - 7 days;
17
               (45)
                        novel influenza virus infection – immediately;
18
               (46)
                        plague - immediately;
19
               (47)
                        paralytic poliomyelitis - 24 hours;
20
               (48)
                        pelvic inflammatory disease – 7 days;
21
               (49)
                        psittacosis - 7 days;
22
               (50)
                        Q fever - 7 days;
23
               (51)
                        rabies, human - 24 hours;
24
               (52)
                        Rocky Mountain spotted fever - 7 days;
25
               (53)
                        rubella - 24 hours;
26
               (54)
                        rubella congenital syndrome - 7 days;
27
               (55)
                        salmonellosis - 24 hours;
28
                        severe acute respiratory syndrome (SARS) – 24 hours;
               (56)
29
                        shigellosis - 24 hours;
               (57)
30
               (58)
                        smallpox - immediately;
31
               (59)
                        Staphylococcus aureus with reduced susceptibility to vancomycin – 24 hours;
32
               (60)
                        streptococcal infection, Group A, invasive disease - 7 days;
33
               (61)
                        syphilis - 24 hours;
```

34

(62)

tetanus - 7 days;

1	(63)	toxic sh	ock syndrome - 7 days;						
2	(64)	trichino	sis - 7 days;						
3	(65)	tubercul	losis - 24 hours;						
4	(66)	tularem	ia – immediately;						
5	(66)	typhoid	- 24 hours;						
6	(67)	typhoid	carriage (Salmonella typhi) - 7 days;						
7	(68)	typhus,	epidemic (louse-borne) - 7 days;						
8	(69)	vaccinia – 24 hours;							
9	(70)	vibrio ii	vibrio infection (other than cholera) – 24 hours;						
10	(71)	whoopi	ng cough – 24 hours; and						
11	(72)	yellow i	Gever - 7 days.						
12	(b) For pur	poses of reporting, "confirmed human immunodeficiency virus (HIV) infection" is defined as a							
13	positive virus cu	ulture, repeatedly reactive EIA antibody test confirmed by western blot or indirect							
14	immunofluoresc	escent antibody test, positive nucleic acid detection (NAT) test, or other confirmed testing method							
15	approved by the	Director of the State Public Health Laboratory conducted on or after February 1, 1990. In selecting							
16	additional tests for approval, the Director of the State Public Health Laboratory shall consider whether such tests								
17	have been approved by the federal Food and Drug Administration, recommended by the federal Centers for Disease								
18	Control and Prev	ontrol and Prevention, and endorsed by the Association of Public Health Laboratories.							
19	(c) In addit	lition to the laboratory reports for Mycobacterium tuberculosis, Neisseria gonorrhoeae, and syphilis							
20	specified in G.S.	cified in G.S. 130A-139, laboratories shall report:							
21	(1)	Isolation or other specific identification of the following organisms or their products from human							
22	clinical	specimens:							
23		(A)	Any hantavirus or hemorrhagic fever virus.						
24		(B)	Arthropod-borne virus (any type).						
25		(C)	Bacillus anthracis, the cause of anthrax.						
26		(D)	Bordetella pertussis, the cause of whooping cough (pertussis).						
27		(E)	Borrelia burgdorferi, the cause of Lyme disease (confirmed tests).						
28		(F)	Brucella spp., the causes of brucellosis.						
29		(G)	Campylobacter spp., the causes of campylobacteriosis.						
30 31		(H)	Chlamydia trachomatis, the cause of genital chlamydial infection, conjunctivitis (adult						
31 32			born) and pneumonia of newborns.						
33		(I)	Clostridium botulinum, a cause of botulism. Clostridium tetani, the cause of tetanus.						
34		(J) (K)	Corynebacterium diphtheriae, the cause of diphtheria.						
35		(K) (L)	Coxiella burnetii, the cause of Q fever.						
36		(M)	Cryptosporidium parvum, the cause of human cryptosporidiosis.						
37		(N)	Cyclospora cayetanesis, the cause of cyclosporiasis.						
		(- ·)	- January and Caracterian of Control of Cont						

patitis B surface antigen. vivax, the causes of malaria in ted fever.					
vivax, the causes of malaria in ted fever.					
vivax, the causes of malaria in ted fever.					
vivax, the causes of malaria in ted fever.					
ted fever.					
ted fever.					
ted fever.					
ted fever.					
ted fever.					
ted fever.					
ted fever.					
ted fever.					
anomycin.					
Isolation or other specific identification of the following organisms from normally sterile human					
sites:					
ei).					
ease.					
ections:					
ections:					
ections:					
ci).					

1				(iii)	Chlamydia psittaci, the cause of psittacosis.			
2				(iv)	Coxiella burnetii, the cause of Q fever.			
3				(v)	Dengue virus.			
4				(vi)	Ehrlichia spp., the causes of ehrlichiosis.			
5				(vii)	Measles (rubeola) virus.			
6				(viii)	Mumps virus.			
7				(ix)	Rickettsia rickettsii, the cause of Rocky Mountain spotted fever.			
8				(x)	Rubella virus.			
9				(xi)	Yellow fever virus.			
10			(B) The presence of IgM serum antibodies to:					
11				(i)	Chlamydia psittaci.			
12				(ii)	Hepatitis A virus.			
13				(iii)	Hepatitis B virus core antigen.			
14				(iv)	Rubella virus.			
15				(v)	Rubeola (measles) virus.			
16				(vi)	Yellow fever virus.			
17		(4)	Labora	tory resul	ts from tests to determine the absolute and relative counts for the T-helper (CD4)			
18		subset	subset of lymphocytes and all results from tests to determine HIV viral load.					
19	(d)	Labora	Laboratories utilizing electronic laboratory reporting (ELR) shall report report:					
20		<u>(1)</u>	All all positive laboratory results from tests used to diagnosis chronic hepatitis C infection,					
21			includi	ng: <u>Hepa</u>	titis C Infection, including the following:			
22			(1)(A)	Hepatit	is C virus antibody tests (including the test specific signal to cut-off (s/c) ratio;			
23			(2) (B)	Hepatit	is C nucleic acid tests;			
24			(3) (C)	Hepatit	is C antigen(s) tests; and			
25			(4) <u>(D)</u>	Hepatit	is C genotypic tests.			
26		(2) All HIV genotypic test results, including when available:						
27			(A)	Th	e entire nucleotide sequence and			
28			(B)	Th	e pol region sequence (including all regions protease (PR)/reverse transcriptase			
29			(RT) ar	nd integra	se inhibitor (INI) genes), if available.			
30								
31								
32								

History Note: Authority G.S. 130A-134; 130A-135; 130A-139; 130A-141

33